What is your current practice for de-escalation of frequency of administration of bispecific antibodies among responders in patients with relapsed/refractory multiple myeloma?

This is a great question. Since the majority of patients respond, I'm not clear of the PFS benefit derived from maintaining dose intensity in patients with ≤ partial response.

The majority of the data regarding de-escalation is from single-arm or registration trials that were not designed to discove...